These results suggest that at the doses administered in this subcutaneous model of pancreatic cancer, the huAR9.6–Gd–DTPA conjugate enabled relatively early detection of MUC16-expressing pancreatic tumor lesions. This evidence concerns the gene MUC16 and familial pancreatic carcinoma.